United States Pulmonary Embolism Market Insights Forecasts to 2033

• The Market Size is Growing at a CAGR of 7.4% from 2023 to 2033
• The US Pulmonary Embolism Market Size is Expected to Hold a Significant Share by 2033

The US Pulmonary Embolism Market Size is Anticipated to Hold a Significant Share by 2033, Growing at a CAGR of 7.4% from 2023 to 2033.

Market Overview

A pulmonary embolism is a blood clot in the lung, which occurs when a clot from another portion of the body, usually in the leg or arm, moves through the bloodstream and gets lodged in the lung's blood arteries. This affects blood flow to the lungs, lowers oxygen levels in the lungs, and raises pulmonary artery blood pressure. Left untreated, PEs may cause heart or lung damage and death. The market is also driven by the expansion through an increase in the R and D activities. This provides beneficial opportunities for the United States pulmonary embolism market growth. Alongside it, the increasing rate of Drug Approvals and launches will again boost the market growth. In addition to this, growth in high-tech investment for the growth of advanced technology and enhancement in the count of growing markets will provide further beneficial growth opportunities for the United States market of pulmonary embolism during the forecast period.

Report Coverage

This research report categorizes the market for United States pulmonary embolism market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United States pulmonary embolism market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the United States pulmonary embolism market.

Driving Factors

The increasing incidence of cancer in the United States pulmonary embolism market makes patients who are undergoing chemotherapy or who have a family history of the condition more vulnerable. This will increase the demand for the drugs, and the industry will grow because more patients are suffering from cancer. The primary cause of lung-related diseases such as pulmonary embolism is long-term smoking addiction. Stress levels in this population base have dramatically increased with the growing rates of urbanization, industrialization, and increased work pressure. This will escalate smoking addiction, and, therefore, the potential of sales in the United States pulmonary embolism market will also increase.

Restraining Factors

Lack of familiarity and knowledge among healthcare service providers and general society regarding pulmonary embolism would lead to a lack of alertness and ignorance to treat it in its early stages which might delay appropriate treatment to be sought at an emergency room.

Market Segment

The U.S. pulmonary embolism market share is classified into drug class and distribution channel.

• The factor Xa inhibitors segment is expected to hold the largest market share through the forecast period.

The US pulmonary embolism market is by drug class into factor Xa inhibitors, thrombin inhibitors, heparin, and others. Among these, the factor Xa inhibitors segment is expected to hold the largest market share through the forecast period. This is attributed to the fact that these drugs are preferably used as anticoagulants for the treatment of blood clots in pulmonary embolism. Apart from this, these drugs treat numerous other conditions related to the disease, including deep vein thrombosis, coronary artery disease, and peripheral artery disease, thus being considered the drug of choice for pulmonary embolism.

• The hospital pharmacies segment is expected to hold the largest market share through the forecast period.

The US pulmonary embolism market is segmented by distribution channel into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment is expected to hold the largest market share through the forecast period. This is attributed to the treatment of pulmonary embolism is usually critical and requires immediate and specialized care in the hospital setting. Hospitals also have access to a more diverse range of medications and advanced therapeutic options compared to retail and online pharmacies.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United States pulmonary embolism market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Eli Lilly and Company
• Merck & Co., Inc.
• Baxter
• AstraZeneca
• Genentech Inc.
• Abbott
• Mylan N.V.
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Private Limited
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at regional, and country levels from 2022 to 2033. Spherical Insights has segmented the United States pulmonary embolism market based on the below-mentioned segments:

United States Pulmonary Embolism Market, By Drug Class

• Factor Xa Inhibitors
• Thrombin Inhibitors
• Heparin
• Others

United States Pulmonary Embolism Market, By Distribution Channel

• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Pharmacies